A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) found a way to switch it back on.

Early detection of ovarian cancer remains a major clinical challenge, as current screening methods often fail to identify disease at a stage when treatment is most effective. Growing evidence indicates that many aggressive ovarian cancers originate in the fallopian tubes, where precursor lesions can persist for years before spreading. Researchers at the University of Arizona have developed a submillimeter Cell‑Acquiring Fallopian Endoscope (CAFE) designed to image the fallopian tubes and collect epithelial cells in a minimally invasive manner. The redesigned device combines white‑light imaging for navigation with reflectance and fluorescence imaging to detect optical changes associated with early disease, while a smooth, lumen‑based collection method gathers cells for cytological or molecular analysis. In an initial ex vivo study of intact human fallopian tubes from three patients, the endoscope successfully navigated the tubes, captured high‑quality images, and collected tens of thousands of cells without visible tissue damage. The results support further studies to evaluate the device’s potential for early ovarian cancer detection, particularly in high‑risk populations.

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be harnessed for cancer therapy.

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.

A new study led by researchers at the University of Liège highlights the unexpected role of Stard7 in the development of intestinal cancers. Long seen as a transporter of some lipids to mitochondria, Stard7 now appears to be a key player in mitochondrial metabolism and tumour development in the intestine.

The National Comprehensive Cancer Network and NCCN Foundation select five Young Investigator Award recipients from Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, O'Neal Comprehensive Cancer Center at UAB, Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, and The University of Texas MD Anderson Cancer Center.

As survival rates for female-specific cancers continue to rise, therapy-related myeloid neoplasms (t-MN) have become a critical long-term complication threatening survivors’ health. This systematic review by the team from Union Hospital summarizes the multi-factorial pathogenesis of t-MN, analyzes current treatment dilemmas, and puts forward female-focused management strategies. It provides a comprehensive theoretical framework for clinical precision prevention, early monitoring and targeted intervention of t-MN.